Orforglipron (Foundayo) is the first nonpeptide, oral, once‑daily GLP‑1 receptor agonist, marking a meaningful shift in GLP‑1 therapy. The nonpeptide structure is clinically significant, as orforglipron does not require fasting.
By contrast, oral semaglutide (Wegovy) is a peptide formulation that relies on SNAC (salcaprozate sodium) to protect the drug from stomach acid and facilitate absorption. Because food dilutes SNAC and significantly reduces bioavailability, oral semaglutide must be taken on an empty stomach first thing in the morning. Orforglipron avoids this limitation, potentially improving convenience, adherence and real‑world utilization.
In late 2025, orforglipron received a Commissioner’s National Priority Voucher, enabling an accelerated FDA review. FDA approval for weight management occurred on April 1, 2026, with a type 2 diabetes indication anticipated in the second half of 2026.
In the ACHIEVE‑3 trial, orforglipron demonstrated greater A1c reduction than oral semaglutide in patients with type 2 diabetes (2.2% vs. 1.4%), while producing comparable weight loss. Gastrointestinal side effects were consistent with the GLP‑1 class and may occur at higher rates; 9% of orforglipron patients discontinued due to adverse events, compared with 5% for oral semaglutide.
Combination Therapy Enters the Competitive Field
CagriSema (Novo Nordisk), a once weekly injectable combination of semaglutide and the long‑acting amylin analogue cagrilintide, is expected to receive FDA approval by late 2026. As the first GLP‑1/amylin combination therapy, CagriSema targets appetite regulation through dual mechanisms.
In the REDEFINE‑1 trial, patients receiving CagriSema achieved greater weight loss than semaglutide alone (22.7% vs. 16.1%). However, in the REDEFINE‑4 head‑to‑head trial, CagriSema did not demonstrate superiority versus tirzepatide (Zepbound). Over 84 weeks, the average weight loss was 25.5% with tirzepatide compared with 23.0% with CagriSema.
Employer Implications
As oral nonpeptide GLP‑1s and combination therapies approach market entry, plan sponsors should anticipate expanded utilization, increased clinical complexity and heightened pressure on cost‑containment strategies. The next phase of GLP‑1 management will hinge less on access and more on formulary strategy, utilization controls and long‑term affordability.
